00:02 , Jan 10, 2017 |  BC Extra  |  Company News

Celgene partners with Anokion, lifts 2017 guidance

Celgene Corp. (NASDAQ:CELG) and Anokion S.A. (Ecublens, Switzerland) partnered to use the Swiss biotech's immune tolerizing platform to develop therapies for autoimmune diseases. Celgene made an equity investment in Anokion and obtained an option to...
07:00 , May 5, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Erythropoietin (EPO); EPO receptor; glycophorin A (GYPA)

Hematology INDICATION: Anemia TARGET/MARKER/PATHWAY: Erythropoietin (EPO); EPO receptor; glycophorin A (GYPA) LICENSING STATUS: Patent and licensing status unavailable PUBLICATION DETAILS: Burrill, D. et al. Proc. Natl. Acad. Sci. USA; published online Apr. 25, 2016 doi:10.1073/pnas.1525388113...
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Conjugation of glycophorin A (GYPA)-binding peptides to protein drugs to reduce anti-drug immunity

Drug delivery TECHNOLOGY: Targeting domains A GYPA-binding peptide that targets therapeutic proteins to erythrocytes could help prevent immune responses to the drugs. In normal mice, injection of asparaginase conjugated to a peptide that binds GYPA...
07:00 , Jun 9, 2014 |  BioCentury  |  Emerging Company Profile

Anokion: Developing tolerance

Anokion S.A. is using its antigen-specific tolerance platform to develop less immunogenic versions of existing drugs. In the longer term, the company wants to use the technology to develop novel autoimmune therapeutics. For existing protein...
07:00 , Jul 14, 1997 |  BioCentury  |  Emerging Company Profile

RedCell: Permanent bonds

Emerging Company Profile RedCell: Permanent bonds Many drugs fail in development because they are rapidly metabolized or cleared from the body too rapidly to have a therapeutic effect. Others must be given at such high...